Inclusion Criteria:

- Patients must have histologically or cytologically confirmed evidence of pancreatic
carcinoma.

- Patients must have had all gross disease resected (R0 or R1 resection).

- Patients who underwent an R2 resection are not eligible.

- Patients must have had no prior chemotherapy or radiation therapy for pancreatic
cancer.

- Age > 18 years.

- Patient must have ECOG performance status of 0-2.

- Patients must have normal organ and marrow function measured within 2 weeks. prior to
registration as follows:

ANC > 1,500/µL Platelets > 100,000/µL Total bilirubim less than 2-fold ULN
AST(SGOT)/ALT(SGPT)<2.5X institutional upper limit of normal Creatinine clearance >
60mL/min for patients with creatinine levels above institutional normal.

- Patients must be > 4 weeks and < 12 weeks post-surgery at time of study registration.

- Women of childbearing potential and sexually active males are stronglt advised to use
appropriate contraceptive measures.

Women must not be pregnant or breast-feeding. All agents used in this study as well as
radiation therapy to the abdomen have the potential for teratogenic or abortifacient
effects. All females of childbearing potential must have a blood test or urine study
within 2 weeks prior to registration to rule out pregnancy.

- Patients must not be receiving any other investigational agents.

- Patients with known metastases are not eligible.

- Patients with wounds that have not fully healed are not eligible.

Exclusion Criteria:

-